GH vs. FTRE, RDNT, VCYT, VRDN, CDNA, FLGT, BNR, PSNL, EXAS, and IOVA
Should you be buying Guardant Health stock or one of its competitors? The main competitors of Guardant Health include Fortrea (FTRE), RadNet (RDNT), Veracyte (VCYT), Viridian Therapeutics (VRDN), CareDx (CDNA), Fulgent Genetics (FLGT), Burning Rock Biotech (BNR), Personalis (PSNL), Exact Sciences (EXAS), and Iovance Biotherapeutics (IOVA).
Fortrea (NASDAQ:FTRE) and Guardant Health (NASDAQ:GH) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation, institutional ownership and community ranking.
Fortrea has a net margin of -4.11% compared to Fortrea's net margin of -76.34%. Guardant Health's return on equity of 4.76% beat Fortrea's return on equity.
Guardant Health received 256 more outperform votes than Fortrea when rated by MarketBeat users. Likewise, 68.75% of users gave Guardant Health an outperform vote while only 47.06% of users gave Fortrea an outperform vote.
Fortrea has higher revenue and earnings than Guardant Health. Fortrea is trading at a lower price-to-earnings ratio than Guardant Health, indicating that it is currently the more affordable of the two stocks.
In the previous week, Fortrea had 20 more articles in the media than Guardant Health. MarketBeat recorded 34 mentions for Fortrea and 14 mentions for Guardant Health. Fortrea's average media sentiment score of 0.68 beat Guardant Health's score of 0.57 indicating that Guardant Health is being referred to more favorably in the news media.
Fortrea currently has a consensus target price of $35.57, suggesting a potential upside of 23.64%. Guardant Health has a consensus target price of $35.78, suggesting a potential upside of 38.94%. Given Fortrea's stronger consensus rating and higher probable upside, analysts clearly believe Guardant Health is more favorable than Fortrea.
92.6% of Guardant Health shares are held by institutional investors. 0.1% of Fortrea shares are held by company insiders. Comparatively, 6.2% of Guardant Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Guardant Health beats Fortrea on 10 of the 18 factors compared between the two stocks.
Get Guardant Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for GH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Guardant Health Competitors List
Related Companies and Tools
